Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term - Ascendis Pharma ( NASDAQ:ASND ) , Biomarin Pharmaceutical ( NASDAQ:BMRN )
Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature. In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity ( ...
| Ticker |
Sentiment |
Impact |
|
BMRN
|
Somewhat Bearish
|
32 %
|
|
ASND
|
Somewhat Bearish
|
21 %
|
